Results 291 to 300 of about 112,056 (332)
A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with gaucher disease and parkinsonism [PDF]
et al, +3 more
core +1 more source
Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes +6 more
wiley +1 more source
A New Phenotype–Genotype Correlation for FIG4 and Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.
Iro Boura +4 more
wiley +1 more source
Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion. [PDF]
Apostolova I +5 more
europepmc +1 more source
Role of alpha-synuclein in the regulation of dopamine neurotransmission in the striatum [PDF]
Chadchankar, Heramb
core

